Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors

Journal of Medicinal Chemistry

Volumn 49, Issue 7, 2006, Pages 2268-2275

  Ye, Yunpeng ^a   Bloch, Sharon ^a   Xu, Baogang ^a   Achilefu, Samuel ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CARBOCYANINE; CYPATE; DICARBOXYLIC ACID; FLUORESCENT DYE; INTEGRIN; LIGAND; RECEPTOR; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; FLUORESCENCE; HUMAN; HUMAN CELL; IMAGING; MOLECULAR INTERACTION; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; TUMOR CELL;

ANIMALS; CARBOCYANINES; CELL LINE; DRUG DESIGN; FLUORESCENT DYES; FLUOROMETRY; HUMANS; INTEGRIN ALPHAVBETA3; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 33645698508     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050947h     Document Type: Article

References (72)

1. Tsuji, T. Physiological and pathological roles of alpha3beta1 integrin. J. Membr. Biol. 2004, 200, 115-132.
2. Gille, J.; Swerlick, R. A. Integrins: Role in cell adhesion and communication. Ann. N. Y. Acad. Sci. 1996, 797, 93-106.
3. Byzova, T. V.; Kim, W.; Midura, R. J.; Plow, E. F. Activation of integrin alpha(v)beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp. Cell Res. 2000, 254, 299-308.
4. Taverna, D.; Crowley, D.; Connolly, M.; Bronson, R. T.; Hynes, R. O. A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res. 2005, 65, 10324-10329.
5. Carreiras, F.; Thiebot, B.; Leroy-Dudal, J.; Maubant, S.; Breton, M. F.; Darbeida, H. Involvement of alpha v beta 3 integrin and disruption of endothelial fibronectin network during the adhesion of the human ovarian adenocarcinoma cell line igrovl on the human umbilical vein cell extracellular matrix. Int. J. Cancer 2002, 99, 800-808.
6. Pedchenko, V.; Zent, R.; Hudson, B. G. Alpha(v)beta3 and alpha-(v)beta5 integrins bind both the proximal rgd site and nonrgd motifs within noncollagenous (ncl) domain of the alpha3 chain of type iv collagen: Implication for the mechanism of endothelia cell adhesion. J. Biol. Chem. 2004, 279, 2772-2780.
7. Pidgeon, G. P.; Tang, K.; Cai, Y. L.; Piasentin, E.; Honn, K. V. Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression. Cancer Res. 2003, 63, 4258-4267.
8. Mousa, S. A.; Forsythe, M.; Bozarth, J.; Jin, F.; Confalone, P. N. Human platelet alphaiibeta3 integrin binding affinity and specificity of SJ874: Antiplatelet efficacy versus aspirin. Coron. Artery Dis. 2000, 11, 563-570.
9. Watson, S. P.; Auger, J. M.; McCarty, O. J. T.; Pearce, A. C. Gpvi and integrin alpha ii beta 3 signaling in platelets. J. Thromb. Haemost. 2005, 3, 1752-1762.
10. Nakamura, I.; Jimi, E. Role of alpha v beta 3 integrins in osteoclast function. Recent Res. Dev. Immunol. 2004, 6, 79-94.
11. Inoue, M.; Namba, N.; Chappel, J.; Teitelbaum, S. L.; Ross, F. P. Granulocyte macrophage-colony stimulating factor reciprocally regulates alphav-associated integrins on murine osteoclast precursors. Mol. Endocrinol. 1998, 12, 1955-1962.
12. Sago, K.; Teitelbaum, S. L.; Venstrom, K.; Reichardt, L. F.; Ross, F. P. The integrin alphavbeta5 is expressed on avian osteoclast precursors and regulated by retinoic acid. J. Bone Miner. Res. 1999, 14, 32-38.
13. Lane, N. E.; Yao, W.; Nakamura, M. C.; Humphrey, M. B.; Kimmel, D.; Huang, X.; Sheppard, D.; Ross, F. P.; Teitelbaum, S. L. Mice lacking the integrin beta5 subunit have accelerated osteoclast maturation and increased activity in the estrogen-deficient state. J. Bone Miner. Res. 2005, 20, 58-66.
14. McHugh, K. P.; Hodivala-Dilke, K.; Zheng, M. H.; Namba, N.; Lam, J.; Novack, D.; Feng, X.; Ross, F. P.; Hynes, R. O.; Teitelbaum, S. L. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 2000, 105, 433-440.
15. Li, X.; Chen, B.; Blystone, S. D.; McHugh, K. P.; Ross, F. P.; Ramos, D. M. Differential expression of alphav integrins in k1735 melanoma cells. Invasion Metastasis 1998, 18, 1-14.
16. Kuphal, S.; Bauer, R.; Bosserhoff, A.-K. Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 2005, 24, 195-222.
17. Bilato, C.; Curto, K. A.; Monticone, R. E.; Pauly, R. R.; White, A. J.; Crow, M. T. The inhibition of vascular smooth muscle cell migration by peptide and antibody antagonists of the alphavbeta3 integrin complex is reversed by activated calcium/calmodulin-dependent protein kinase ii. J. Clin. Invest. 1997, 100, 693-704.
18. Kintscher, U.; Lyon, C.; Wakino, S.; Bruemmer, D.; Xu, F.; Goetze, S.; Graf, K.; Moustakas, A.; Staels, B.; Fleck, E.; Hsueh, W. A.; Law, R. E. Ppar alpha inhibits tgf-beta-induced beta(5) integrin transcription in vascular smooth muscle cells by interacting with smad4. Circ. Res. 2002, 91, E35-E44.
19. Lygoe, K. A.; Norman, J. T.; Marshall, J. F.; Lewis, M. P. Alphav integrins play an important role in myofibroblast differentiation. Wound Repair Regen. 2004, 12, 461-470.
20. Pierschbacher, M. D.; Ruoslahti, E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984, 309, 30-33.
21. Pierschbacher, M. D.; Hayman, E. G.; Ruoslahti, E. The cell attachment determinant in fibronectin. J. Cell. Biochem. 1985, 28, 115-126.
22. Ruoslahti, E.; Pierschbacher, M. D. Arg-gly-asp: A versatile cell recognition signal. Cell 1986, 44, 517-518.
23. Ruoslahti, E. The rgd story: A personal account. Matrix Biol. 2003, 22, 459-465.
24. Busk, M.; Pytela, R.; Sheppard, D. Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein. J. Biol. Chem. 1992, 267, 5790-5796.
25. Paik, J.-Y.; Ko, B.-H.; Yearn, S. C.; Choi, Y.; Lee, K.-H.; Kim, B.-T. Pma-enhanced neutrophil [18f]fdg uptake is independent of integrin occupancy but requires pi3k activity. Nucl. Med. Biol. 2005, 32, 561-566.
26. Bergh, J. J.; Lin, H.-Y.; Lansing, L.; Davis, F. B.; Davis, P. J.; Mohamed, S. N.; Mousa, S. Integrin alpha v beta 3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005, 146, 2864-2871.
27. Fondevila, C.; Shen, X. D.; Moore, C.; Busuttil, R. W.; Coito, A. J. Cyclic rgd peptides with high affinity for alpha 5 beta 1 integrin protect genetically fat zucker rat livers from cold ischemia/reperfusion injury. Transplant. Proc. 2005, 37, 1679-1681.
28. Haubner, R.; Wester, H. J.; Burkhart, F.; Senekowitsch-Schmidtke. R.; Weber, W.; Goodman, S. L.; Kessler, H.; Schwaiger, M. Glycosylated rgd-containing peptides, tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 2001, 42, 326-336.
29. Aumailley, M.; Gurrath, M.; Muller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-gly-asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment p1. FEBS Lett. 1991, 291, 50-54.
30. Dechantsreiter, M. A.; Planker, E.; Matha, B.; Lohof, E.; Holzemann, G.; Jonczyk, A.; Goodman, S. L.; Kessler, H. N-Methylated cyclic rgd peptides as highly active and selective alpha(v)beta(3) integrin antagonists. J. Med. Chem. 1999, 42, 3033-3040.
31. Haubner, R.; Kuhnast, B.; Mang, C.; Weber, W. A.; Kessler, H.; Wester, H. J.; Schwaiger, M. F-18 galacto-rgd: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjugate Chem. 2004, 15, 61-69.
32. Nisato, R. E.; Tille, J. C; Jonczyk, A.; Goodman, S. L.; Pepper, M. S. Alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003, 6, 105-119.
33. Enns, A.; Korb, T.; Schluter, K.; Gassmann, P.; Spiegel, H. U.; Senninger, N.; Mitjans, F.; Haier, J. Alphavbeta5-integrins mediate early steps of metastasis formation. Eur. J. Cancer 2005, 41, 1065-1072.
34. Kessler, T.; Bieker, R.; Padro, T.; Schwoppe, C.; Persigehl, T.; Bremer, C.; Kreuter, M.; Berdel, W. E.; Mesters, R. M. Inhibition of tumor growth by rgd peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin. Cancer Res. 2005, 11, 6317-6324.
35. Mitra, A.; Mulholland, J.; Nan, A.; McNeill, E.; Ghandehari, H.; Line, B. R. Targeting tumor angiogenic vasculature using polymer-rgd conjugates. J. Controlled Release 2005, 102, 191-201.
36. Tucker, G. C. Alpha v integrin inhibitors and cancer therapy. Curr. Opin. Investig. Drugs 2003, 4, 722-731.
37. Achilefu, S. Lighting up tumors with receptor-specific optical molecular probes. Technol. Cancer Res. Treat. 2004, 3, 393-409.
38. Weissleder, R.; Tung, C. H.; Mahmood, U.; Bogdanov, A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat. Biotechnol. 1999, 17, 375-378.
39. Chen, X.; Conti, P. S.; Moats, R. A. In vivo near-infrared fluorescence imaging of integrin alpha v beta 3 in brain tumor xenografts. Cancer Res. 2004, 64, 8009-8014.
40. Wang, W.; Ke, S.; Wu, Q.; Charnsangavej, C.; Gelovani, J. G.; Abbruzzese, J. L.; Li, C.; Gurfinkel, M.; Sevick-Muraca, E. M. Near-infrared optical imaging of integrin alpha v beta 3 in human tumor xenografts. Mol. Imaging 2004, 3, 343-351.
41. Burnett, C. A.; Xie, J.; Quijano, J.; Hunter, F.; Bur, M.; Li, K. C. P.; Danthi, S. N.; Shen, Z. Synthesis, in vitro, and in vivo characterization of an integrin alpha v beta 3-targeted molecular probe for optical imaging of tumor. Bioorg. Med. Chem. 2005, 13, 3763-3771.
42. Achilefu, S.; Bloch, S.; Markiewicz, M. A.; Zhong, T. X.; Ye, Y. P.; Dorshow, R. B.; Chance, B.; Liang, K. X. Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 7976-7981.
43. Bloch, S.; Liang, K.; Dorshow, R. B.; Ye, Y.; Achilefu, S. Targeting the expression of integrin receptors in tumors. Proc. SPIE 2004, 5329, 222-228.
44. Sharma, S. D.; Jiang, J. W.; Hadley, M. E.; Bentley, D. L.; Hruby, V. J. Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors. Proc. Natl. Acad Sci. U.S.A. 1996, 93, 13715-13720.
45. Mammen, M.; Choi, S. K.; Whitesides, G. M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed 1998, 37, 2755-2794.
46. Roy, R. A decade of glycodendrimer chemistry. Trends Glycosci. Glycotechnol. 2003, 15, 291-310.
47. Sacchettini, J. C.; Baum, L. G.; Brewer, C. F. Multivalent protein-carbohydrate interactions. A new paradigm for supermolecular assembly and signal transduction. Biochemistry 2001, 40, 3009-3015.
48. Burridge, K.; Chrzanowska-Wodnicka, M. Focal adhesions, contractility, and signaling. Annu. Rev. Cell Dev. Biol. 1996, 12, 463-518.
49. Thumshirn, G.; Hersel, U.; Kessler, H.; Goodman, S. L. Multimeric cyclic rgd peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation. Chem.-Eur. J. 2003, 9, 2717-2725.
50. Boturyn, D.; Garanger, E.; Dumy, P.; Coll, J.-L.; Favrot, M.-C. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J. Am. Chem. Soc. 2004, 126, 5730-5739.
51. Dirksen, A.; Langereis, S.; De Waal, B. F. M.; Van Genderen, M. H. P.; Meijer, E. W.; Hackeng, T. M. A supramolecular approach to multivalent target-specific mri contrast agents for angiogenesis. Chem. Commun. 2005, 2811-2813.
52. Winnard, P., Jr.; Raman, V. Real time noninvasive imaging of receptor-ligand interactions in vivo. J. Cell. Biochem. 2003, 90, 454-463.
53. Leamon, C. P.; Reddy, J. A. Folate-targeted chemotherapy. Adv. Drug. Delivery Rev. 2004, 56, 1127-1141.
54. Ke, C. Y.; Mathias, C. J.; Green, M. A. Folate-receptor-targeted radionuclide imaging agents. Adv. Drug. Delivery Rev. 2004, 56, 1143-1160.
55. Cheng, Z.; Wu, Y.; Xiong, Z.; Gambhir, S. S.; Chen, X. Near-infrared fluorescent rgd peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjugate Chem. 2005, 16, 1433-1441.
56. Tung, C. H.; Lin, Y. H.; Moon, W. K.; Weissleder, R. A receptor-targeted near-infrared fluorescence probe for in vivo tumor imaging. Chembiochem 2002, 3, 784-786.
57. Gottschalk, K.-E.; Kessler, H. The structures of integrins and integrin-ligand complexes: Implications for drug design and signal transduction. Angew. Chem.. Int. Ed. 2002, 41, 3767-3774.
58. Ye, Y.; Li, W. P.; Anderson, C. J.; Kao, J.; Nikiforovich, G. V.; Achilefu, S. Synthesis and characterization of a macrocyclic near-infrared optical scaffold. J. Am. Chem. Soc. 2003, 125, 7766-7767.
59. Ye, Y. P.; Bloch, S.; Achilefu, S. Polyvalent carbocyanine molecular beacons for molecular recognitions. J. Am. Chem. Soc. 2004, 126, 7740-7741.
60. Ye, Y.; Bloch, S.; Kao, J.; Achilefu, S. Multivalent carbocyanine molecular probes: Synthesis and applications. Bioconjugate Chem. 2005, 16, 51-61.
61. Kumar, C. C.; Nie, H. M.; Rogers, C. P.; Malkowski, M.; Maxwell, E.; Catino, J. J.; Armstrong, L. Biochemical characterization of the binding of echistatin to integrin alpha(v)beta(3) receptor. J. Pharmacol. Exp. Ther. 1997, 283, 843-853.
62. Achilefu, S.; Dorshow, R. B.; Bugaj, J. E.; Rajagopalan, R. Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Invest. Radial. 2000, 35, 479-485.
63. Bugaj, J. E.; Achilefu, S.; Dorshow, R. B.; Rajagopalan, R. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J. Biomed. Opt. 2001, 6, 122-133.
64. Cordes, N.; Beinke, C.; Plasswilm, L.; van Beuningen, D. Irradiation and various cytotoxic drugs enhance tyrosine phosphorylation and beta(1)-integrin clustering in human a549 lung cancer cells in a substratum-dependent manner in vitro. Strahlenther. Onkol. 2004, 180, 157-164.
65. Oyama, T.; Sykes, K. F.; Samli, K. N.; Minna, J. D.; Johnston, S. A.; Brown, K. C. Isolation of lung tumor specific peptides from a random peptide library: Generation of diagnostic and cell-targeting reagents. Cancer Lett. 2003, 202, 219-230.
66. Lubin, F. D.; Segal, M.; McGee, D. W. Regulation of epithelial cell cytokine responses by the alpha 3 beta 1 integrin. Immunology 2003, 108, 204-210.
67. Davison, E.; Kirby, I.; Whitehouse, J.; Hart, I.; Marshall, J. F.; Santis, G. Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with ad(5) fibre binding is mediated by alpha(v)beta(1) integrin and can be modulated by changes in beta(1) integrin function. J. Gene. Med. 2001, 3, 550-559.
68. Triantafilou, K.; Triantafilou, M.; Takada, Y.; Fernandez, N. Human parechovirus 1 utilizes integrins alpha v beta 3 and alpha v beta 1 as receptors. J. Virol. 2000, 74, 5856-5862.
69. Allen, C. M.; Sharman, W. M.; La Madeleine, C.; Weber, J. M.; Langlois, R.; Quellet, R.; van Lier, J. E. Photodynamic therapy: Tumor targeting with adenoviral proteins. Photochem. Photohiol. 1999, 70, 512-523.
70. Pottratz, S. T.; Weir, A. L. Gamma-interferon inhibits pneumocystis carinii attachment to lung cells by decreasing expression of lung cell-surface integrins. Eur. J. Clin. Invest. 1997, 27, 17-22.
71. Reilly, P. L.; Woska, J. R.; Jeanfavre, D. D.; McNally, E.; Rothlein, R.; Bormann, B. J. The native structure of intercellular-adhesion molecule-1 (icam-1) is a dimer - correlation with binding to lfa-1. J. Immunol 1995, 155, 529-532.
72. Bai, M.; Campisi, L.; Freimuth, P. Vitronectin receptor antibodies inhibit infection of hela and a549 cells by adenovirus-type-12 but not by adenovirus type-2. J. Virol. 1994, 68, 5925-5932.